MedRhythms partners with Biogen to develop, commercialize mobility PDT

Date:

Share:

Prescription digital therapeutics startup MedRhythms has entered into a licensing agreement with Biogen to develop and commercialize its MR-004 product, which aims to improve mobility for people with multiple sclerosis (MS).

Under the deal, MedRhythms would receive a $3 million upfront payment from Biogen, with the potential to earn up to $117.5 million if certain development and commercial milestones are met. The startup is also eligible to receive tiered royalties based on sales.

The MR-004 therapeutic aims to treat gait deficits, a mobility problem that occurs with MS that can make it difficult to walk. In 2020, MedRhythms received FDA Breakthrough Device Designation for its product focused on chronic stroke walking impairments. It uses sensors to measure how well a user can walk to the beat of a song and adjusts the tempo based on those metrics to improve outcomes.

“At MedRhythms, we are committed to redefining what is possible for people living with neurologic diseases by building evidence-based products that meaningfully impact symptoms that have been underserved by traditional treatment modalities,” the company’s CEO Brian Harris said in a statement. “We look forward to what our collaboration with Biogen, a global leader in MS, could mean for the patients we serve around the world.”

WHY IT MATTERS

According to the National Multiple Sclerosis Society, difficulty walking is one of the more common mobility concerns with MS, and people with the disease are prone to falls that can cause injuries. 

“As part of our aspiration in digital health, together with MedRhythms we aim to advance a new, innovative treatment option for people living with MS that may help address walking impairment, a common issue that impacts their overall quality of life,” Martin Dubuc, head of Biogen Digital Health, said in a statement.

“Pioneering in digital therapeutics exemplifies Biogen’s commitment to advance novel therapies that we hope will improve outcomes for people living with MS.”

THE LARGER TREND

MedRhythms raised $25 million in Series B funding in July last year, bringing its total raise to $34 million. This also isn’t the company’s first commercialization partnership. About a year ago, it began working with life sciences commercial services company Eversana to launch its chronic stroke tool. 

Meanwhile, MedRhythms isn’t alone in striking deals with traditional pharma players for digital therapeutics. Swedish startup Alex Therapeutics, which raised €3.5 million last month, offers a platform that aims to help pharma and life science partners create and launch digital therapeutics. Early this year, the company entered into a strategic commercial partnership with Pfizer, initially focused on creating digital therapeutics for nicotine addiction treatment.

Sidekick Health, which just announced a $55 million Series B, has inked deals with Pfizer and Bayer. Happify Health recently announced a partnership with healthcare services and pharmaceutical company Zuellig Pharma to commercialize two of its prescription digital therapeutics in Asia.

━ more like this

23andMe posts $217M net loss during ‘transitional’ fiscal year

23andMe reported a $217 million net loss during its fiscal year 2022, which ended March 31, compared with $184 million during the prior year.  The...

Study: VR therapeutic reduces pain intensity long term, compared with sham app

A virtual reality therapeutic program reduces pain intensity up to six months later, compared with a sham app, according to a study published in...

Roundup: Telehealth platform for endometriosis launched in Malaysia, India upgrades health ID app, and more briefs

Bayer launches telehealth platform for endometriosis in Malaysia Pharmaceutical firm Bayer has partnered with digital health company DoctorOnCall and the Endometriosis Association of Malaysia (MyEndosis)...

Clinical trial tech company uMotif scores $22.5M to continue international expansion

Patient data capture and clinical trial tech company uMotif announced Wednesday it had secured $25.5 million from a fund managed by Athyrium Capital Management. The...

Transcarent hires chief marketing officer from Fitbit and more digital health hires

Transcarent, a healthcare platform focused on self-insured employers, has appointed Tim Rosa as chief marketing officer. Rosa comes to Transcarent from health-tracking wearable maker Fitbit,...

LEAVE A REPLY

Please enter your comment!
Please enter your name here